156 related articles for article (PubMed ID: 38090808)
21. Ductal carcinoma in situ: treatment or active surveillance?
Kuerer HM
Expert Rev Anticancer Ther; 2015; 15(7):777-85. PubMed ID: 25938920
[TBL] [Abstract][Full Text] [Related]
22. Predicting Upgrade of Ductal Carcinoma In Situ to Invasive Breast Cancer at Surgery With Ultrafast Imaging.
Miceli R; Gao Y; Qian K; Heller SL
AJR Am J Roentgenol; 2023 Jul; 221(1):34-43. PubMed ID: 36752370
[No Abstract] [Full Text] [Related]
23. Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies.
Hanna WM; Parra-Herran C; Lu FI; Slodkowska E; Rakovitch E; Nofech-Mozes S
Mod Pathol; 2019 Jul; 32(7):896-915. PubMed ID: 30760859
[TBL] [Abstract][Full Text] [Related]
24. Breast ductal carcinoma in situ with micro-invasion versus ductal carcinoma in situ: a comparative analysis of clinicopathological and mammographic findings.
Zhang M; Lin Q; Su XH; Cui CX; Bian TT; Wang CQ; Zhao J; Li LL; Ma JZ; Huang JL
Clin Radiol; 2021 Oct; 76(10):787.e1-787.e7. PubMed ID: 34052010
[TBL] [Abstract][Full Text] [Related]
25. Evolving paradigm for imaging, diagnosis, and management of DCIS.
Wells CJ; O'Donoghue C; Ojeda-Fournier H; Retallack HE; Esserman LJ
J Am Coll Radiol; 2013 Dec; 10(12):918-23. PubMed ID: 24295941
[TBL] [Abstract][Full Text] [Related]
26. Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?
Rosso KJ; Weiss A; Thompson AM
Surg Oncol Clin N Am; 2018 Jan; 27(1):69-80. PubMed ID: 29132566
[TBL] [Abstract][Full Text] [Related]
27. Should low-risk DCIS lose the cancer label? An evidence review.
Ma T; Semsarian CR; Barratt A; Parker L; Pathmanathan N; Nickel B; Bell KJL
Breast Cancer Res Treat; 2023 Jun; 199(3):415-433. PubMed ID: 37074481
[TBL] [Abstract][Full Text] [Related]
28. Imaging for the diagnosis and management of ductal carcinoma in situ.
D'Orsi CJ
J Natl Cancer Inst Monogr; 2010; 2010(41):214-7. PubMed ID: 20956833
[TBL] [Abstract][Full Text] [Related]
29. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
30. Trends in detection of invasive cancer and ductal carcinoma in situ at biennial screening mammography in Spain: a retrospective cohort study.
Román M; Rué M; Sala M; Ascunce N; Baré M; Baroja A; De la Vega M; Galcerán J; Natal C; Salas D; Sánchez-Jacob M; Zubizarreta R; Castells X;
PLoS One; 2013; 8(12):e83121. PubMed ID: 24376649
[TBL] [Abstract][Full Text] [Related]
31. Avoiding Overtreatment of Ductal Carcinoma in situ.
van der Borden CL; Stoffers S; Lips EH; Wesseling J
Trends Cancer; 2019 Jul; 5(7):391-393. PubMed ID: 31311652
[TBL] [Abstract][Full Text] [Related]
32. Long-term Surveillance of Ductal Carcinoma in Situ Detected with Screening Mammography versus US: Factors Associated with Second Breast Cancer.
Choi SH; Choi JS; Han BK; Ko EY; Ko ES; Park KW
Radiology; 2019 Jul; 292(1):37-48. PubMed ID: 31038406
[TBL] [Abstract][Full Text] [Related]
33. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
[TBL] [Abstract][Full Text] [Related]
34. Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS.
Nicholson S; Hanby A; Clements K; Kearins O; Lawrence G; Dodwell D; Bishop H; Thompson A;
Eur J Surg Oncol; 2015 Jan; 41(1):86-93. PubMed ID: 25441934
[TBL] [Abstract][Full Text] [Related]
35. Valuing preferences for treating screen detected ductal carcinoma in situ.
Bromley HL; Mann GB; Petrie D; Nickson C; Rea D; Roberts TE
Eur J Cancer; 2019 Dec; 123():130-137. PubMed ID: 31689678
[TBL] [Abstract][Full Text] [Related]
36. Patterns of aggressiveness: risk of progression to invasive breast cancer by mammographic features of calcifications in screen-detected ductal carcinoma in situ.
Lilleborge M; Falk RS; Hovda T; Holmen MM; Ursin G; Hofvind S
Acta Radiol; 2022 May; 63(5):586-595. PubMed ID: 33887963
[TBL] [Abstract][Full Text] [Related]
37. Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features?
Shi B; Grimm LJ; Mazurowski MA; Baker JA; Marks JR; King LM; Maley CC; Hwang ES; Lo JY
Acad Radiol; 2017 Sep; 24(9):1139-1147. PubMed ID: 28506510
[TBL] [Abstract][Full Text] [Related]
38. Addressing overtreatment of screen detected DCIS; the LORIS trial.
Francis A; Thomas J; Fallowfield L; Wallis M; Bartlett JM; Brookes C; Roberts T; Pirrie S; Gaunt C; Young J; Billingham L; Dodwell D; Hanby A; Pinder SE; Evans A; Reed M; Jenkins V; Matthews L; Wilcox M; Fairbrother P; Bowden S; Rea D
Eur J Cancer; 2015 Nov; 51(16):2296-303. PubMed ID: 26296293
[TBL] [Abstract][Full Text] [Related]
39. Screening mammography-detected ductal carcinoma in situ: mammographic features based on breast cancer subtypes.
Kim MY; Kim HS; Choi N; Yang JH; Yoo YB; Park KS
Clin Imaging; 2015; 39(6):983-6. PubMed ID: 26259866
[TBL] [Abstract][Full Text] [Related]
40. Assessment of grating-based X-ray phase-contrast CT for differentiation of invasive ductal carcinoma and ductal carcinoma in situ in an experimental ex vivo set-up.
Sztrókay A; Herzen J; Auweter SD; Liebhardt S; Mayr D; Willner M; Hahn D; Zanette I; Weitkamp T; Hellerhoff K; Pfeiffer F; Reiser MF; Bamberg F
Eur Radiol; 2013 Feb; 23(2):381-7. PubMed ID: 22932738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
